When a family hears that cancer has spread inside the abdomen, the next thought is rarely about which drug will be used. It is about distance — how far the treatment is, how many trips it will take, and whether anyone in the public system nearby can do it. In Bathinda, that second question may now have a different answer.
A peritoneal cancer unit is now standing at AIIMS Bathinda
AIIMS Bathinda has set up a dedicated peritoneal cancer unit, and the facility is equipped with the RanD Performer 3 HIPEC System. That machine is the working core of the unit: it heats and circulates chemotherapy solution through the abdominal cavity during a procedure known as HIPEC.
The system, as described, supports controlled heating, circulation and temperature monitoring of the solution during the procedure — three things that decide whether the treatment is delivered safely and evenly.
The machine is the story here, and here is why
HIPEC, or hyperthermic intraperitoneal chemotherapy, is not a standard chemotherapy session. It is delivered during surgery, after visible deposits have been removed, with the drug solution warmed and circulated directly inside the abdomen rather than through a vein.
Temperature and circulation cannot be eyeballed. They have to be measured, held steady and adjusted in real time, which is exactly the role the RanD Performer 3 is designed to perform. A unit without such a device is a room; a unit with one is a functioning programme.
Peritoneal cancer: the disease this unit is built around
Peritoneal cancer is cancer that involves the peritoneum, the thin lining that wraps the organs and walls of the abdominal cavity. In many patients it is not where the cancer began.
It is more often the spread of disease from the ovary, colon, stomach or appendix — which is why the diagnosis usually lands on families already in the middle of cancer treatment, often after a scan that changes everything.
Who this actually reaches — and who it may not
The immediate gain is geographic. Patients in and around Bathinda have historically had to look toward larger tertiary centres elsewhere in Punjab, Chandigarh or Delhi for advanced abdominal oncologic surgery.
But a unit is more than equipment. It needs surgical oncologists trained in cytoreductive surgery, anaesthetists comfortable with long operations, perfusion expertise, intensive care beds and structured follow-up. Those details have not been made public here.
What AIIMS Bathinda has confirmed, and what it has not
On the public record so far, the confirmed elements are narrow but clear: the unit exists, and it is equipped with the RanD Performer 3 HIPEC System with heating, circulation and temperature-monitoring capabilities.
What has not been detailed includes the number of dedicated beds, the composition of the treating team, patient selection criteria, the cost to patients, and whether treatment will be offered free or subsidised under existing government schemes.
Confirmed Facts vs What Remains Unclear
Confirmed: A peritoneal cancer unit has been set up at AIIMS Bathinda. It is equipped with the RanD Performer 3 HIPEC System. The device heats and circulates chemotherapy solution through the abdominal cavity during HIPEC, with controlled heating, circulation and temperature monitoring.
Unclear: When the unit begins accepting patients, how many procedures it can handle, who is eligible, and at what cost. Anything beyond the above — including claims about it being the first of its kind in the region or the number of patients treated — has not been established and should be treated as unverified.
The cost question families will ask first
HIPEC is a resource-intensive procedure: a long operation, a perfusion circuit, specialist drugs and often a stretch in intensive care. In private settings, that combination is expensive, which is precisely why public-sector availability matters.
Whether this unit reduces the financial burden depends entirely on the pricing and scheme coverage that AIIMS Bathinda applies — information that is not yet in the public domain.
Where this fits in the wider cancer care picture
HIPEC has existed in India for years, largely at selected high-volume cancer centres, and access has been uneven across states and between private and public systems.
What is notable here is the setting: not a metro institution, but a government AIIMS in a regional district. If such units are sustained — with trained teams and steady case volumes — specialised oncology slowly stops being a journey outward.
What patients and families should do now
If you or a family member has been told that cancer has spread to the peritoneum, the practical step is not to assume the new unit will automatically take the case. Ask your treating oncologist whether HIPEC is medically indicated for this specific cancer type, stage and general fitness.
Then ask about the referral route to AIIMS Bathinda, what documents and imaging will be required, whether a multidisciplinary review is needed first, and what the expected cost and waiting period are. This article reports a development; it is not medical advice, and treatment decisions belong with your oncology team.
What could happen next
The likely next milestones are procedural rather than dramatic: referrals beginning to move, a surgical oncology team being formally identified, and eventually case data being published or discussed at medical forums.
If those steps follow, the unit moves from being an installation to a functioning service. If they do not, the equipment remains what it is today — a necessary first step.
Our Take
The significance of this announcement is not the machine alone. It is the signal that peritoneal surface malignancy — a category often dismissed as too advanced or too expensive to treat in a government setting — is being planned for at a regional AIIMS.
The honest caveat is that announcements of this kind are easy to make and hard to run. HIPEC outcomes depend on surgical skill and case volume far more than on hardware, and those numbers will only be visible a year or two from now. For patients in the Malwa belt, the door has been opened. Whether it stays open is the part that will be measured.
Frequently Asked Questions
What is the new peritoneal cancer unit at AIIMS Bathinda?
It is a dedicated facility at AIIMS Bathinda for treating cancers involving the peritoneum, the lining of the abdominal cavity. It is equipped with the RanD Performer 3 HIPEC System, which heats and circulates chemotherapy solution inside the abdomen during surgery.
What is the RanD Performer 3 HIPEC System?
It is a specialised perfusion device used during HIPEC procedures. It heats the chemotherapy solution, circulates it through the abdominal cavity, and monitors temperature so the treatment is delivered under controlled conditions.
What exactly is HIPEC treatment?
HIPEC stands for hyperthermic intraperitoneal chemotherapy. It is delivered during surgery, after visible tumour deposits are removed, by circulating warmed chemotherapy drugs directly inside the abdomen rather than through a vein.
Does this mean patients no longer need to travel outside Punjab?
Not automatically. Availability depends on whether the unit has a trained surgical oncology team, functioning intensive care support and a clear referral process. Those operational details have not been publicly confirmed, so patients should check with their treating oncologist before assuming treatment can be done locally.
Is HIPEC suitable for every abdominal cancer patient?
No. HIPEC is offered only for specific cancer types, stages and patients who are medically fit enough to tolerate a long, complex operation. Suitability is decided case by case by a multidisciplinary oncology team, not by diagnosis alone.
